Genmab — September 2019

[E_L]

We are developing, in collaboration with Genmab, novel next-generation bispecific antibodies that are designed for conditional activation of immunostimulatory checkpoint molecules. Our first bispecific candidates are GEN1046 (BNT311), which targets PD-L1 in conjunction with 4-1BB, and GEN1042 (BNT312), which targets CD40 in conjunction with 4-1BB

[E_L]

While 4-1BB is a known immune checkpoint target that is expressed on T cells and natural killer, or NK, cells, prior attempts to target 4-1BB with monoclonal antibodies have been severely limited by liver toxicities. Our 4-1BB targeting product candidates are designed to avoid toxicities by conditionally activating a 4-1BB receptor only together with the binding of either PD-L1 or CD40. We have initiated Phase 1/2a trials of GEN1046 (BNT311) and GEN1042 (BNT312) in solid tumors.

[E_L]

interesting on the liver toxicity which Jan also mentioned before

[E_L]

and also GEN1042 has initiated according to this

[E_L]

it was taken out of clinicaltrials a while ago, as you may remember. (I understand on a recent investor conference in Holland, Jan said that it is the next product candidate planned for the clinic)

[JohnW]

Are GEN1046 and GEN1042 both Genmab products?

[JohnW]

(hence the prefix?)

[E_L]

50:50 cost and profit share with Genmab

[E_L]

with GEN1046 it reads "executed by Genmab" so I guess Genmab mostly in charge

[E_L]

GEN1042 "We and Genmab began recruitment and screening for a Phase 1/2a trial of GEN1042 (BNT312) for the treatment of malignant solid tumors in August 2019." - so it
started

[Sukkeralf]

They pulled back the IND and made a CTA instead - so the trial on GEN1042 will be made in Europe

[E_L]

ah, ok, thanks

[E_L]

so i guess we keep following this one instead of clinicaltrials US https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003716-47/DK

[Sukkeralf]

yes sir

[AaBforever]

Vi skal sikkert ned i 1270 igen.

[E_L]

Bryan, Garnier : GENMAB - BUY | DKK1450(+4%)

Data-Driven Medicine is getting more traction

Agreement to identify new disease targets/biomarkers
DDM getting more traction among the pharma/biotech industry
Recipe for success: network is a key

[Helge_LarsenPI-redaktør]

Et sundstegn at phama falder i kurs: https://penge.borsen.dk/artikel/1/387482/chef_aktieanalytiker_sundhedstegn_for_aktiemarkedet_at_novo_nordisk_falder.html

[Vitus]

Hvorfor skal vi ikke længere ned end 1270 igen ?

[Helge_LarsenPI-redaktør]

Fordi på 1.270 går Aab´s Bulls i minus.

[Vitus]

Det tror jeg nu ikke der bliver taget hensyn til....